Global Cardiac Biomarkers Testing 麻豆原创 Research Report 2023

Publication ID:

PB504245217

Publication Date:

May 5, 2023

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Medical Devices [2]

Pharma & Healthcare [3]

Description:

Cardiac biomarkers are the substances released into the blood stream from the damaged muscle of the heart.
Highlights
The global Cardiac Biomarkers Testing market was valued at US$ 7817 million in 2022 and is anticipated to reach US$ 11410 million by 2029, witnessing a CAGR of 6.5% during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Cardiac biomarkers are the substances released into the blood stream from the damaged muscle of the heart. These biomarkers are used to diagnose heart functioning, risk stratifications, and cardiac diseases in patients. Biomarker is a quantifiable and measurable biological parameter that includes an enzyme, hormones, and proteins, all associated with heart function, failure, or damage.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Cardiac Biomarkers Testing, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Cardiac Biomarkers Testing.
The Cardiac Biomarkers Testing market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Cardiac Biomarkers Testing market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Cardiac Biomarkers Testing companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
Abbott Laboratories
Becton, Dickinson and Company
BioMerieux
Bio-Rad Laboratories, Inc.
Danaher Corporation
ROCHE
Siemens AG
Thermo Fisher Scientific, Inc.
PerkinElmer Inc.
Tosoh Corporation
Segment by Type
Myocardial Muscle Creatine Kinase (CK-MB)
Troponins (T and I)
Myoglobin
Brain Natriuretic Peptide (BNPs) or NT-proBNP
Ischemia-modified Albumin (IMA)
Others
Segment by Application
Myocardial Infarction
Congestive Heart Failure
Acute Coronary Syndrome
Atherosclerosis
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Cardiac Biomarkers Testing companies鈥� competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Cardiac Biomarkers Testing 麻豆原创 Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Myocardial Muscle Creatine Kinase (CK-MB)
1.2.3 Troponins (T and I)
1.2.4 Myoglobin
1.2.5 Brain Natriuretic Peptide (BNPs) or NT-proBNP
1.2.6 Ischemia-modified Albumin (IMA)
1.2.7 Others
1.3 麻豆原创 by Application
1.3.1 Global Cardiac Biomarkers Testing 麻豆原创 Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Myocardial Infarction
1.3.3 Congestive Heart Failure
1.3.4 Acute Coronary Syndrome
1.3.5 Atherosclerosis
1.3.6 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Cardiac Biomarkers Testing 麻豆原创 Perspective (2018-2029)
2.2 Cardiac Biomarkers Testing Growth Trends by Region
2.2.1 Global Cardiac Biomarkers Testing 麻豆原创 Size by Region: 2018 VS 2022 VS 2029
2.2.2 Cardiac Biomarkers Testing Historic 麻豆原创 Size by Region (2018-2023)
2.2.3 Cardiac Biomarkers Testing Forecasted 麻豆原创 Size by Region (2024-2029)
2.3 Cardiac Biomarkers Testing 麻豆原创 Dynamics
2.3.1 Cardiac Biomarkers Testing Industry Trends
2.3.2 Cardiac Biomarkers Testing 麻豆原创 Drivers
2.3.3 Cardiac Biomarkers Testing 麻豆原创 Challenges
2.3.4 Cardiac Biomarkers Testing 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top Cardiac Biomarkers Testing Players by Revenue
3.1.1 Global Top Cardiac Biomarkers Testing Players by Revenue (2018-2023)
3.1.2 Global Cardiac Biomarkers Testing Revenue 麻豆原创 Share by Players (2018-2023)
3.2 Global Cardiac Biomarkers Testing 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Cardiac Biomarkers Testing Revenue
3.4 Global Cardiac Biomarkers Testing 麻豆原创 Concentration Ratio
3.4.1 Global Cardiac Biomarkers Testing 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Cardiac Biomarkers Testing Revenue in 2022
3.5 Cardiac Biomarkers Testing Key Players Head office and Area Served
3.6 Key Players Cardiac Biomarkers Testing Product Solution and Service
3.7 Date of Enter into Cardiac Biomarkers Testing 麻豆原创
3.8 Mergers & Acquisitions, Expansion Plans
4 Cardiac Biomarkers Testing Breakdown Data by Type
4.1 Global Cardiac Biomarkers Testing Historic 麻豆原创 Size by Type (2018-2023)
4.2 Global Cardiac Biomarkers Testing Forecasted 麻豆原创 Size by Type (2024-2029)
5 Cardiac Biomarkers Testing Breakdown Data by Application
5.1 Global Cardiac Biomarkers Testing Historic 麻豆原创 Size by Application (2018-2023)
5.2 Global Cardiac Biomarkers Testing Forecasted 麻豆原创 Size by Application (2024-2029)
6 North America
6.1 North America Cardiac Biomarkers Testing 麻豆原创 Size (2018-2029)
6.2 North America Cardiac Biomarkers Testing 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Cardiac Biomarkers Testing 麻豆原创 Size by Country (2018-2023)
6.4 North America Cardiac Biomarkers Testing 麻豆原创 Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Cardiac Biomarkers Testing 麻豆原创 Size (2018-2029)
7.2 Europe Cardiac Biomarkers Testing 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Cardiac Biomarkers Testing 麻豆原创 Size by Country (2018-2023)
7.4 Europe Cardiac Biomarkers Testing 麻豆原创 Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Cardiac Biomarkers Testing 麻豆原创 Size (2018-2029)
8.2 Asia-Pacific Cardiac Biomarkers Testing 麻豆原创 Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Cardiac Biomarkers Testing 麻豆原创 Size by Region (2018-2023)
8.4 Asia-Pacific Cardiac Biomarkers Testing 麻豆原创 Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Cardiac Biomarkers Testing 麻豆原创 Size (2018-2029)
9.2 Latin America Cardiac Biomarkers Testing 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Cardiac Biomarkers Testing 麻豆原创 Size by Country (2018-2023)
9.4 Latin America Cardiac Biomarkers Testing 麻豆原创 Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Cardiac Biomarkers Testing 麻豆原创 Size (2018-2029)
10.2 Middle East & Africa Cardiac Biomarkers Testing 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Cardiac Biomarkers Testing 麻豆原创 Size by Country (2018-2023)
10.4 Middle East & Africa Cardiac Biomarkers Testing 麻豆原创 Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Abbott Laboratories
11.1.1 Abbott Laboratories Company Detail
11.1.2 Abbott Laboratories Business Overview
11.1.3 Abbott Laboratories Cardiac Biomarkers Testing Introduction
11.1.4 Abbott Laboratories Revenue in Cardiac Biomarkers Testing Business (2018-2023)
11.1.5 Abbott Laboratories Recent Development
11.2 Becton, Dickinson and Company
11.2.1 Becton, Dickinson and Company Company Detail
11.2.2 Becton, Dickinson and Company Business Overview
11.2.3 Becton, Dickinson and Company Cardiac Biomarkers Testing Introduction
11.2.4 Becton, Dickinson and Company Revenue in Cardiac Biomarkers Testing Business (2018-2023)
11.2.5 Becton, Dickinson and Company Recent Development
11.3 BioMerieux
11.3.1 BioMerieux Company Detail
11.3.2 BioMerieux Business Overview
11.3.3 BioMerieux Cardiac Biomarkers Testing Introduction
11.3.4 BioMerieux Revenue in Cardiac Biomarkers Testing Business (2018-2023)
11.3.5 BioMerieux Recent Development
11.4 Bio-Rad Laboratories, Inc.
11.4.1 Bio-Rad Laboratories, Inc. Company Detail
11.4.2 Bio-Rad Laboratories, Inc. Business Overview
11.4.3 Bio-Rad Laboratories, Inc. Cardiac Biomarkers Testing Introduction
11.4.4 Bio-Rad Laboratories, Inc. Revenue in Cardiac Biomarkers Testing Business (2018-2023)
11.4.5 Bio-Rad Laboratories, Inc. Recent Development
11.5 Danaher Corporation
11.5.1 Danaher Corporation Company Detail
11.5.2 Danaher Corporation Business Overview
11.5.3 Danaher Corporation Cardiac Biomarkers Testing Introduction
11.5.4 Danaher Corporation Revenue in Cardiac Biomarkers Testing Business (2018-2023)
11.5.5 Danaher Corporation Recent Development
11.6 ROCHE
11.6.1 ROCHE Company Detail
11.6.2 ROCHE Business Overview
11.6.3 ROCHE Cardiac Biomarkers Testing Introduction
11.6.4 ROCHE Revenue in Cardiac Biomarkers Testing Business (2018-2023)
11.6.5 ROCHE Recent Development
11.7 Siemens AG
11.7.1 Siemens AG Company Detail
11.7.2 Siemens AG Business Overview
11.7.3 Siemens AG Cardiac Biomarkers Testing Introduction
11.7.4 Siemens AG Revenue in Cardiac Biomarkers Testing Business (2018-2023)
11.7.5 Siemens AG Recent Development
11.8 Thermo Fisher Scientific, Inc.
11.8.1 Thermo Fisher Scientific, Inc. Company Detail
11.8.2 Thermo Fisher Scientific, Inc. Business Overview
11.8.3 Thermo Fisher Scientific, Inc. Cardiac Biomarkers Testing Introduction
11.8.4 Thermo Fisher Scientific, Inc. Revenue in Cardiac Biomarkers Testing Business (2018-2023)
11.8.5 Thermo Fisher Scientific, Inc. Recent Development
11.9 PerkinElmer Inc.
11.9.1 PerkinElmer Inc. Company Detail
11.9.2 PerkinElmer Inc. Business Overview
11.9.3 PerkinElmer Inc. Cardiac Biomarkers Testing Introduction
11.9.4 PerkinElmer Inc. Revenue in Cardiac Biomarkers Testing Business (2018-2023)
11.9.5 PerkinElmer Inc. Recent Development
11.10 Tosoh Corporation
11.10.1 Tosoh Corporation Company Detail
11.10.2 Tosoh Corporation Business Overview
11.10.3 Tosoh Corporation Cardiac Biomarkers Testing Introduction
11.10.4 Tosoh Corporation Revenue in Cardiac Biomarkers Testing Business (2018-2023)
11.10.5 Tosoh Corporation Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Companies Mentioned:

Abbott Laboratories
Becton, Dickinson and Company
BioMerieux
Bio-Rad Laboratories, Inc.
Danaher Corporation
ROCHE
Siemens AG
Thermo Fisher Scientific, Inc.
PerkinElmer Inc.
Tosoh Corporation

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.